What are the risks of stopping suddenly after three months of taking regorafenib?

Abrupt discontinuation of regorafenib after three months of treatment may result in disease rebound or accelerated disease progression. Regorafenib is an oral multi-target tyrosine kinase inhibitor mainly used for the treatment of advanced colorectal cancer, gastrointestinal stromal tumors and hepatocellular carcinoma. Its mechanism of action is to control cancer cell proliferation by inhibiting tumor angiogenesis and signaling pathways. Once the drug is stopped suddenly, the drug concentration in the body drops rapidly, and the tumor cells may become active again, leading to the risk of disease recurrence or rapid progression.

Abrupt discontinuation of medication may also cause previously manageable symptoms to worsen again. While patients are taking regorafenib, the drug can partially relieve tumor-related symptoms, such as pain, weight loss, or discomfort related to tumor burden. Once the drug is discontinued, these symptoms may quickly appear or worsen, affecting the patient's quality of life. At the same time, some patients may experience compensatory reactions related to angiogenesis, which can reactivate tumor blood vessels and aggravate disease progression.

Additionally, stopping the medication suddenly may increase the risk of a stress response in the body. After long-term medication, the patient's body has adapted to the effects of the medication, including the regulation of blood pressure, liver function, heart and other systems. Once the drug is stopped, blood pressure fluctuations, abnormal liver function indicators, or other systemic discomforts may occur, which require close observation and management. For patients with chronic diseases, such sudden physiological changes require even greater caution.

Therefore, it is clinically recommended that regorafenib should be discontinued by gradually reducing the dose or adjusting the regimen under the guidance of a doctor, rather than interrupting suddenly. By gradually stopping the drug, the body and tumors can gradually adapt to the withdrawal of the drug, reducing the risk of disease recurrence and adverse reactions. When discontinuing medication or adjusting the treatment plan, patients should maintain close communication with their attending physician and regularly monitor disease progression and physical indicators to ensure the safety and continuity of treatment.

Reference link:https://www.drugs.com

xa0